Introducton
Heart disease, comprising ischemic heart disease and congestive heart failure, is not only the leading cause of death and lost life expectancy in most Western countries but also one of the most important causes of morbidity and health care costs.1 After a period of increasing mortality during the 1950s and 1960s, Western countries have witnessed a dramatic decline of ischemic heart disease mortality (age-adjusted), with the United States taking the lead.2 Though the dynamics are not completely understood, time trends in known risk factors for ischemic heart disease (hypertension, cholesterol, smoking) in Western countries indicate a clear decline. [3] [4] [5] Therefore it is reasonable to attribute at least part ofthis decrease in mortality to a decrease in incidence.
The observed sharp decline in mortality, together with the probable decline in incidence, leads one to expect a concomitant decrease in health care utilization. In reality, however, health care providers all over the Western world are facing increases in demand. After the introduction of percutaneous transluminal coronary angioplasties, utilization ofthese procedures increased almost exponentially, while the growth in utilization of coronary artery bypass graft surgery merely slowed.6 Viewed superficially, the observed increases in demand are incongruent with the supposed decrease in need.
But is need truly decreasing? Basic epidemiologic theory teaches us that if mortality slows faster than incidence, prevalence will increase. Although the Framingham Heart Study has shown a small decline in incidence, a strong increase in prevalence has been observed, indicative of a survival gain.3 This improved prognosis has been caused partly by improved risk factor distributions, but medical therapy has also contributed. 7, 8 Recently, beta-blocking agents, platelet aggregation inhibitors, coronary artery bypass graft surgery, and angiotensine converting enzyme inhibitors have been applied in chronic therapy and thrombolytic therapy has been applied in emergencies. All have been proven effective in randomized controlled trials meeting high standards.-11 If trends in risk factors and survival remain favorable, the further decrease in incidence and mortality of ischemic heart disease is likely to be accompanied by a continuing increase in prevalence. In Westem countries, the increased prevalence will be accentuated by the aging of the baby boom generation born after World War II. This cohort will soon reach middle age with its concomitant heart disease risks: the increase in age-specific prevalence will be accompanied by an increase in sheer size of the older age groups.
To make a quantitative analysis of the dynamics of the heart disease epidemic, we developed a simulation model for the most important manifestations of ischemic heart disease and congestive heart failure. Available information from the medical literature was combined with data obtained from mortality and morbid-Heart-Disease M bdt ity registers. We explored the future of heart disease morbidity in the Netherlands in different scenarios. The morbidity model consists of three main sectors: the first-month model, the ischemic heart disease model, and the congestive heart failure model. Persons developing heart disease, the rate ofwhich is dependent on age and sex, move into the first-month model, which characterizes the initial event and its immediate sequelae during the first 30 days following the onset of disease. Persons in whom congestive heart failure forms the first heart disease event move directly into the appropriate model. Survivors of the first 30 days enter the ischemic heart disease model or the congestive heart failure model that describes the remaining 11 months of the first year and all subsequent years. Persons with ischemic heart disease can move into the congestive heart failure model, but not vice versa. Death from heart disease is modeled through the specific transition probabilities of the model. In all prevalent states, persons are subjected to an additional risk of death from all other causes, corrected for heart disease, that is based on national life tables. 14 The first-month model covers the month immediately after the initial cardiac disease event (Figure 1 ). This event may be angina pectoris, an acute coronary event (an acute myocardial infarction or cardiac arrest), or congestive heart failure.
Methods

Model
Persons suffering a first acute coronary event may die before reaching a health care facility (deaths before admission).
Once taken into care, they are subjected to a further death risk (deaths in hospital). If the person survives the coronary event, the pump function of the heart may be permanently impaired. Patients with heart failure after an acute myocardial infarction enter the congestive heart failure model; the others move into the ischemic heart disease model. Persons with a first diagnosis of uncomplicated angina pectoris or congestive heart failure proceed to the ischemic heart disease and congestive heart failure models, respectively.
On entry, the ischemic heart disease model distinguishes between angina pectoris and acute coronary event states. Conditional on these states, patients face possible new events in the 2 to 12 months after the first incident. These events range from acute coronary events to coronary artery bypass grafts to percutaneous transluminal coronary angioplasties to all possible combinations of these. Each combination of events in a state has a probability of sudden death from ischemic heart disease dependent on the current event, the current state (and therefore the ischemic heart disease history), and the patient's age and sex. The patients also risk heart failure as a sequel of an acute coronary event ("ACE + CHF" in the figure) or as a consequence of chronic ischemic damage; these patients move into the congestive heart failure model. If none of the above occurs, patients will remain in the ischemic heart disease model.
After this first year, patients remaining in the ischemic heart disease model are reclassified into four new states, conditional on previous disease history. These Note. CHF = congestive heart failure; ACE = acute coronary event; IHD = ischemic heart disease; CABG = coronary artery bypass graft; PTCA = percutaneous transluminal coronary angioplasty. Heart Failure Heart failure due to ischemic heart disease is caused by acute events or by chronic ischemic damage. Eighteen percent of ischemic heart disease patients survive an acute myocardial infarction with irreversible heart failure as a sequel.33.34 The distribution by age, sex, and previous ischemic heart disease history is assumed to be the same as the distnbution of in-hospital mortality by age, sex, and previous ischemic heart disease history after an acute myocardial infarction. The annual probabilities of developing congestive heart failure, given a history of ischemic heart disease, were estimated from the Framingham Heart Study data. 17 We obtained the published annual event rates of 1.5% given an uncomplicated angina pectoris history and 3.0%o given a history of an acute coronary event and adjusted to allow for the number of acute cases caused by an acute coronary event.
The age distribution was calculated by applying relative risks of 3.0 (angina pectoris) and 5.0 (acute myocardial infarction) to the age-specific incidence data taken from the Framingham study. 17 The incidence rates of congestive heart failure for persons without a history ofischemic heart disease are calculated by assuming that persons in whom congestive heart failure is the certified cause of death survived their first diagnosis of congestive heart failure for 5 (males) to 7 (females) years. 11, 12, 1517 Heart Disease Mortalit
The total age-and sex-specific inhospital mortality rates 
All persons in all states are subject to the risk of dying of other diseases, adjusted to allow for the causes of death under study and based on Dutch life tables.
Resuds
Calculated Estimates for 1985 Figure 2 shows the observed and simulated events of acute myocardial infarction: total admissions and deaths in and outside the hospital, by age and sex. The model closely reproduces the observed data. The gap between simulated and observed rates in the older age groups represents persons with recognized acute myocardial infarctions who are not admitted to a hospital. Calculated prevalences of heart disease by age and sex are shown in Figure 3 . Heart disease is more concentrated in the oldest age groups in women, whereas the burden of morbidity in the male population is already high at middle age. The leveling off and decrease by age in the prevalence ofclinical ischemic heart disease in men shown in the figure is caused by the steep rise in the incidence of congestive heart failure and sudden cardiac death, reducing clinical ischemic heart disease incidence. Prevalence of all heart disease reaches 25% in the age groups 70 through 74 years (men) and 80 through 84 years (women). Women suffer relatively more often than men from angina pectoris and congestive heart failure, but less often from severe ischemic heart disease. This pattern has been confirmed time and again in many surveys.32'49'3X Projections for Disease-specific mortality is the direct result of incidence and survival. If two ofthese elements are known, the third can be calculated. Because the decline in ischemic heart disease mortality that has been observed since 1975 is indisputable, we postulated an ongoing decline of this mortality into the near future. We provide three plausible scenarios, based on varying assumptions of further decreasing incidence rates and improving prognoses (see Table 2 ).
The reference scenario, based on the Framingham Heart Study, supposes that one third of the mortality decline is explained by a decline in incidence (-1.0% per year) and that two thirds is explained American Joumal of Public Health 23 by an increase in survival.3,4,8.9,26,51 In an extreme low-incidence-change scenario, we assume that the incidence decrease is even less: -0.5% per year. This is the magnitude of change predicted by a risk factor model, based on changes in risk factor prevalences in the Netherlands.5 In an extreme high-incidence-change scenario, we assume a high decrease in incidence (-1.7% per year).
We have projected these trends over the period 1985 through 2010 to juxtapose the effects of demographic and epidemiologic change.
The results are summarized in Figures 4 through 6 and Table 3 . Figure 4 shows how the decreasing incidence, together with the increase in survival, results in lower prevalence rates in the young and increasing prevalence rates in older age groups. In the youngest (30-to 39-year-old) age group, the decrease will be about 25%; in the oldest old (85 years and older), prevalence will increase by 20% for men and 10% for women. Superimposing the population projections on these figures results in a completely different picture, which is shown in the same figure. The movement ofthe postwar baby boom generation into middle age and the sharp increase in the number of the very elderly is clearly revealed. Together with the projected increase in prevalence rates, this demographic change will result in a steep climb in the number of heart disease patients in the oldest age groups. Hence, while epidemiological changes in cardiovascular disease will result in an increase of 10% to 20% in prevalence rates for the oldest old (85 years and older), the absolute number of patients will more than double. Figures 5 and 6 show the projected changes in age-specific prevalences for different types of ischemic heart disease; Figure 5 shows the relative changes in rates and Figure 6 shows the absolute changes in numbers. The change in agespecific rates for all ischemic heart disease combined is the same as in Figure 4 . Figure 5 shows a relative increase of severe ischemic heart disease. Milder stages of the disease act as a risk factor for the more severe stages. If survival increases in all disease stages, effects will culminate in the most serious stages: as more patients stay alive with ischemic heart disease, more will have the opportunity to develop congestive heart failure. Figure 6 shows the changes in absolute terms: the relative decrease of prevalence at younger ages has hardly any impact because of the low number of patients with 24 American Joumal of Public Health Note. "Uncomplicated AP" is defined as angina pectoris only, wfthu a history of acute myocardial inftion. "IHD witou CHF' describes all patients with a hstoxy of ischemic heart disease but without congestve heart failure. "All IHD" compris all ischemic heart disease, including pafients who developed congestive heart failure after ischemic heart disease. "AlI heart disease" summarizes all three conditions. The difference between all heart disease and all ischemkc heart disease shows the prevalence of congestive heart failure. ischemic heart disease at early ages. However, the combination of aging and increasing survival of heart disease leads to a flood of middle-aged men with ischemic heart disease followedby a slowerwave of elderly persons with heart failure. Table 3 shows expected changes in age-standardized rates, using the European Standard Population as the standard, and in absolute numbers, combining the rates with the expected population dynamics in the Netherlands. The mortality decline (observed between 1975 and 1990 and projected over the next 20 years) is so strong that it will be evident even when expressed in absolute numbers. Although the assumed decline in incidence of first myocardial infarctions, which accounts for one third of the decline in mortality, is too small to counteract the aging of the Dutch population, the rate of all myocardial infarctions together will nevertheless decrease substantially. This decrease is the result of the combined decline in incidence and recurrence; the better survival, on the other hand, through which the number of patients at higher risk of recurrent infarctions is increased, is not strong enough to counteract this decline. Because more patients will stay alive and at risk for interventions and reinterventions andbecause ofthe aging ofthe population, the need for coronary artery bypass graft surgery and percutaneous transluminal coronaiy angioplasty will increase by 1% per year (range: 0.4%o-1.6%). The agestandardized prevalence ratios for milder ischemic heart disease tend to decrease, but those for ischemic heart disease complicated by congestive heart failure increase strongly: in absolute numbers, a growth of more than 70%o is to be expected.
Discussion
Simulation modeling provides quantitative insight into epidemiological and public health dynamics and potential future developments. The information needed for these models can never be sup scenarios.3,4,8 These assumptions influence the absolute magnitude of the expected changes, but not the direction. Declining incidence rates mean that the onset of disease is postponed but not halted. The delay in occurrence causes a reduction of morbidity in the young, which, however, is canceled out with age. Mortality is deferred to an even greater extent, owing to a combination of the decrease in incidence and improved prognosis. This mortality decrease will be traded off for a steep increase of more severe morbidity in the old.
Changes in demography will prevent a decrease ofnew cases ofheart disease. 13 However, while age-specific incidence rates show a decline, acute myocardial infarction rates will drop more steeply, owing to a reduction in both incidence and recurrence rates; the increasing prevalences are insufficient to cancel these reductions. The reference scenario predicts a decline in acute myocardial infarction rates that will be sufficiently strong to offset population aging; this development has been observed in the Netherlands since 1985.19-21 But although disease incidence rates are declining, intervention rates will remain unchanged, even assuming that intervention rates per group of patients in a certain disease state remain constant. The reason is that more patients will survive and, on average, survival is longer, resulting in more people in disease states who are eligible for invasive coronary revascularization procedures.
The overall picture emerging from the heart disease scenarios is one of transition from an acute to a more chronic disease: event rates are declining steeply, but the postponed mortality is traded off for increased morbidity and severity of disease among the elderly. This pattern can be observed in hospital admission rates in the Netherlands, in data from the National Health Interview Survey in the United States, and in data from the National Health Survey of Japan.19-53 All of these data show increasing prevalences of ischemic heart disease. As a consequence, overall health care needs will continue to rise, regardless of declining mortality and incidence.
These calculations, based on empirical observations, shed a new light on Fries' compression of morbidity theory. 54 The compression of morbidity theory hinges on the proposition that the incidence of disease will be postponed more rapidly than mortality. For heart disease, the evidence suggests that the decline of lethality expands the number of years January 1994, Vol. 84, No. 1 spent with heart disease morbidity, regardless of the incidence postponement. Healthy life expectancy is extended, as expected by Fries and assumed by the scenarios, but contrary to his prediction, total life expectancy is extended even further. Among the middle-aged and elderly, acute heart disease lethality in the Netherlands is high, increasing sharply with age. Obviously, herewould appear to be a serious potential for reduction. In 1985, for example, the model calculated that 41% of the 70-year-old men died within 4weeks oftheir first acute coronary event.20-24 In our scenarios 32% (range: 30%-34%) are predicted to die within the same period in the year 2010, which in our view remains a conservative estimate. Because heart disease is concentrated in the older age groups, even small differences in the rates of change in incidence and mortality can have major consequences, particularly now that pushing back mortality has been shown to be counterbalanced by an increase in the more severe stages of heart disease. With short-term case-fatality subsequent to an acute event as high as it is, lowering these rates will remain an important goal ofhealth care intervention. Should this aim be successful, the resulting increase in the number of survivors will boost heart disease morbidity and lengthen life expectancy with disease.
Only if health care interventions aimed at reducing mortality subsequent to the event should prove a waste of time and money would no expansion of morbidity be expected. O
